Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers

American Journal of Transplantation

Volumn 14, Issue 8, 2014, Pages 1908-1911

  Danziger Isakov, L ^a   Bucavalas, J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; pediatric transplantation; preemptive therapy; prophylaxis

Indexed keywords

ACICLOVIR; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EVIDENCE BASED PRACTICE; HIGH RISK PATIENT; HUMAN; INFANT; LIVER TRANSPLANTATION; LOW RISK PATIENT; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; WEB BROWSER; ANALOGS AND DERIVATIVES; COMPLICATION; CYTOLOGY; CYTOMEGALOVIRUS INFECTIONS; DONOR; LIVER FAILURE; POSTOPERATIVE COMPLICATION; PROCEDURES; QUESTIONNAIRE; RISK; T LYMPHOCYTE; TIME; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; PEDIATRICS; POSTOPERATIVE COMPLICATIONS; QUESTIONNAIRES; RISK; T-LYMPHOCYTES; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84904612168     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12755     Document Type: Review

References (11)

1. Bedel AN, Hemmelgarn TS, Kohli R., Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012; 18: 347-354.
2. Krampe K, Briem-Richter A, Fischer L, et al. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosuppressive regimen. Pediatr Transplant 2010; 14: 67-71.
3. Kullberg-Lindh C, Ascher H, Krantz M, Lindh M., Quantitative analysis of CMV DNA in children the first year after liver transplantation. Pediatr Transplant 2003; 7: 296-301.
4. Turmelle YP, Nadler ML, Anderson CD, Doyle MB, Lowell JA, Shepherd RW., Towards minimizing immunosuppression in pediatric liver transplant recipients. Pediatr Transplant 2009; 13: 553-559.
5. Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009; 87: 1318-1324.
6. Englesbe MJ, Kelly B, Goss J, et al. Reducing pediatric liver transplant complications: A potential roadmap for transplant quality improvement initiatives within North America. Am J Transplant 2012; 12: 2301-2306.
7. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG., Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381.
8. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360.
9. Lapidus-Krol E, Shapiro R, Amir J, et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010; 14: 753-760.
10. Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. Transplantation 2011; 92: 930-935.
11. Lauer MS, D'Agostino RB Sr., The randomized registry trial-The next disruptive technology in clinical research ? N Engl J Med 2013; 369: 1579-1581.